- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00785967
Immune Responses in Patients Treated With Raltegravir (RAG-1/2)
Immune Responses to Neo-Antigens in Patients Treated With Raltegravir: Insights on V(D)J Recombination and RAG-1/2 Recombinase Function
Hypothesis: Treatment with raltegravir does not alter V(D)J recombination or immune responses to neoantigens.
A process known as V(D)J recombination is essential for developing lymphocytes and the specific functioning of the immune system. Raltegravir is the first approved drug of the new integrase inhibitor class of anti-HIV drugs. Integrase inhibitors have been shown in some studies to interfere with DNA cleavage and the activities of RAG-1/2. These studies suggest a potential to affect aspects of both B-cell and T-cell development, therefore, it is important to evaluate the potential effects that integrase inhibitors may have in clinical use. If immunoglobulin and T-cell receptor genes are altered by HIV integrase, then patient lymphocytes will fail to display normal responses to vaccinations.
Study Overview
Detailed Description
V(D)J recombination is essential for developing lymphocytes and the specific functioning of the immune system. Germline gene coding segments become rearranged to create functional immunoglobulin and T-cell receptor genes by this recombination. The process depends on site-specific cleavage of chromosomal DNA by RAG-1 and RAG-2 recombinase. Two recombination-activating gene proteins (RAG-1/2) in conjunction make up a complex of enzymes that join gene segments of B-cell and T-cell receptor genes. RAG-1 contains most of the V(D)J recombinase active site and RAG-2 is essential in joining DNA segments during V(D)J recombination. RAG-1/2 have similarity in action to other DNA transposases and HIV-1 integrase. These similarities suggest that HIV-1 integrase inhibitors may have the potential to affect aspects of both B-cell and T-cell development.
Induction of primary immune responses to neoantigens involves the generation of specific T-cells and immunoglobulin M (IgM) antibody secreting B-cells. As part of this process, T and B memory cells are also generated, which have specific cell surface receptors to the antigen. On repeat exposure to the antigen, these memory T- and B-cells are triggered to generate rapid and intense secondary responses. During this secondary response, B-cells secrete abundant specific IgG antibodies with greater affinity to the antigen than for the IgM isotope. This memory response is mediated by T-cells with CD45+ RO+ phenotype. These T-cells provide B-cells the help required to generate the specific IgG. Sub-optimal antibody responses are seen in both acquired and hereditary immunodeficiency, which are due to impaired T-cell function including poor T-helper responses to B-cells and defective neo-antigen responses.
An established method to evaluate T-cell function involves testing antibody production to vaccination with phiX174, a stable bacteriophage of E. Coli that is critical in demonstrating T-cell competence. Antibody titers after primary and secondary immunization correlate with abnormal CD4 cell help. Patients with functional B-cells that lack T-cell help show a characteristic failure to switch from IgM to IgG, making this assay essential in the evaluation of V(D)J recombination.
Currently, raltegravir is the only approved integrase inhibitor that targets the integration stage of the HIV-1 lifecycle. The clinical manifestations of raltegravir-related potential adverse effects on V(D)J recombination may be so rare that they may only be observed after large numbers of patients are exposed to this drug. Evaluating the direct in vivo interaction of HIV integrase inhibitors on RAG-1/2 is difficult, therefore the best approach may be to evaluate the potential negative effects on recombinase activity downstream by studying immune function. If gene rearrangements of immunoglobulin and T-cell receptor genes are altered by HIV integrase, then patient lymphocytes will fail to display normal responses to neo-antigen exposure. Since untreated HIV-infected individuals have an impaired ability to respond to new antigens, it is difficult to evaluate the responses to neo-antigens in these individuals. Therefore, to test this hypothesis, it would be best to choose patients with long-term control of HIV that have recovered immune function.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University Health Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1 infected males, as determined by ELISA and Western blot;
- >18 years of age;
- Current ARV therapy with efavirenz + Truvada® for >52 weeks;
- HIV-1 RNA (bDNA) <50 copies/ml for at least 52 weeks;
- No history of hepatitis A vaccine, and HAV antibody negative.
Exclusion Criteria:
- any immunomodulatory therapy within 24 weeks of screening or during the trial;
- any type of vaccine within 24 weeks of screening or during the trial;
- current opportunistic infection, malignancy, acute infection, or febrile illness;
- history of hypersensitivity to a vaccine, components of a vaccine, or components of a vaccine container.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
raltegravir 400mg bid + Truvada 1 tab qd
|
VAQTA: 1.0ml IM at weeks 24 & 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
Other Names:
|
Active Comparator: 2
efavirenz 600mg qhs + Truvada 1 tab qd (or Atripla 1 tab qhs)
|
VAQTA: 1.0ml IM at weeks 24 & 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent of patients with phiX174 IgG greater than or equal to 30% of total anti-phiX174 titers
Time Frame: Two weeks after fourth phiX174 immunization
|
Two weeks after fourth phiX174 immunization
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total phiX174 antibody titers
Time Frame: 2 and 4 weeks after each immunization
|
2 and 4 weeks after each immunization
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christos M Tsoukas, MD, FRCPC, McGill University Health Centre/Research Institute of the McGill University Health Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- MK0518-048-00, Version 2.2
- HC-TPD Control # 120132
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Various vaccines
-
MedtronicNeuroCompletedDeep Brain Stimulation | Spinal Cord Stimulation | Sacral Neuromodulation | Drug Infusion (Implantable Pumps)United States, France, Spain, Germany, United Kingdom, Italy, Austria
-
Seattle Children's HospitalImmunexpressCompletedSepsis | Non-Infectious Systemic Inflammatory Response SyndromeUnited States
-
University of MinnesotaRecruitingChronic Pain | Spinal Cord InjuriesUnited States
-
Sohag UniversityCompleted
-
PfizerOptum, Inc.; RTI Health SolutionsRecruiting
-
Maastricht UniversityActive, not recruitingHealth and Wellbeing of Primary School-aged ChildrenNetherlands
-
Institut PasteurGerman Cancer Research Center; Versailles Saint-Quentin-en-Yvelines University and other collaboratorsCompletedInfection by Human Papilloma VirusFrance
-
Hong Kong Metropolitan UniversityNot yet recruiting
-
Jan KluytmansMedImmune LLC; Universiteit AntwerpenCompletedPneumonia | Nosocomial Pneumonia | Pneumonia, Ventilator-AssociatedNetherlands
-
Massachusetts General HospitalHarvard School of Public Health (HSPH)Completed